Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pictilisib dimethanesulfonate (GDC-0941 2 MeSO3H salt) 是一种 PI3Kα/δ抑制剂,IC50值为 3 nM。对 p110β 和 p110γ的选择性分别为11倍和25倍。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 139 | 现货 | ||
5 mg | ¥ 298 | 现货 | ||
10 mg | ¥ 493 | 现货 | ||
25 mg | ¥ 615 | 现货 | ||
50 mg | ¥ 742 | 现货 | ||
100 mg | ¥ 1,180 | 现货 | ||
200 mg | ¥ 1,840 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 543 | 现货 |
产品描述 | Pictilisib dimethanesulfonate (GDC-0941 2 MeSO3H salt) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold). |
靶点活性 | mTOR:0.58 μM (Ki), p110α-E545K:3 nM, p110α:3 nM, p110γ:75 nM, DNA-PK:1.23 μM, p110δ:3 nM, p110α-H1047R:3 nM, p110β:33 nM |
体外活性 | Pictilisib (GDC-0941) is highly efficacious in combination with U0126 in inducing cell growth inhibition, G0-G1 arrest and cell apoptosis. H460 cells with activating mutations of PIK3CA are relatively more sensitive to Pictilisib (GDC-0941) compared to A549 cells with wild-type PIK3CA. Pictilisib (GDC-0941) reduces PI3K pathway activity in both cell lines, illustrated by decreased pAK. Pictilisib (GDC-0941) significantly reduces secreted VEGF detected in the medium after hypoxic/anoxic exposure in all cells. Pictilisib and RP-56976 reduce tumor cell viability by 80% or greater in the breast cancer cell lines than single-agent treatment. GDC-0941 inhibits Akt phosphorylation and downstream targets of Akt signaling such as pPRAS40 and pS6 in Hs578T1.2 (PI3Kα wild-type), MCF7-neo/HER2 (PI3Kα-mutant), and MX-1 (PTEN-null) tumor models. Pictilisib (GDC-0941) decreases the time of RP-56976-induced mitotic arrest prior to apoptosis. Pictilisib (GDC-0941) shows a high efficacy of antitumor activity in two ZD1839-resistant non-small cell lung cancer (NSCLC) cell lines, A549 and H460. |
体内活性 | Tumours in the Pictilisib (GDC-0941)-treated mice exhibit a significant non-linear shrinkage, and when the Pictilisib (GDC-0941) treatment ceased, the tumours in the test cohort mice grow again. GDC-0941Pictilisib (GDC-0941) (25 or 50 mg/kg) reduces tumor growth and PI3K and HIF-1 pathway activity in eGFP-FTC133 tumor-bearing mice.Pictilisib (GDC-0941) (150 mg/kg, p.o.) leads to tumor stasis in MCF7-neo/HER2-bearing animals model. Pictilisib (GDC-0941) and RP-56976 result in tumor regressions during the treatment period leading to enhanced antitumor responses. |
别名 | GDC-0941 dimethanesulfonate, GDC-0941 2 MeSO3H salt |
分子量 | 705.85 |
分子式 | C25H35N7O9S4 |
CAS No. | 957054-33-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (70.84 mM), Sonication is recommended.
H2O: < 0.1 mg/mL (insoluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.4167 mL | 7.0837 mL | 14.1673 mL | 35.4183 mL |
5 mM | 0.2833 mL | 1.4167 mL | 2.8335 mL | 7.0837 mL | |
10 mM | 0.1417 mL | 0.7084 mL | 1.4167 mL | 3.5418 mL | |
20 mM | 0.0708 mL | 0.3542 mL | 0.7084 mL | 1.7709 mL | |
50 mM | 0.0283 mL | 0.1417 mL | 0.2833 mL | 0.7084 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Pictilisib dimethanesulfonate 957054-33-0 Apoptosis Autophagy DNA Damage/DNA Repair PI3K/Akt/mTOR signaling DNA-PK PI3K mTOR GDC 0941 inhibit Inhibitor GDC-0941 dimethanesulfonate Pictilisib GDC0941 GDC-0941 2 MeSO3H Phosphoinositide 3-kinase GDC-0941 2 MeSO3H salt GDC-0941 inhibitor